627. Aggressive Lymphomas: Clinical and Epidemiological: Real World evidence for CAR-T Management II


Ana Alarcon Tomas, Joshua A Fein, Shalev Fried, et al.

The most extensive and detailed experience of treatment outcomes post-CAR-T therapy are presented. For more info see abstract. New drugs may be preferable to traditional chemotherapy as the first treatment after CAR-T, even if survival is still poor. The authors present an instrument that provides information about the mortality risk in this difficult-to-treat population group.



Joanna C. Zurko, Narendranath Epperla, Imran Nizamuddin, et al.

The authors present the largest reported analysis of patients with aggressive B-cell lymphoma who develop PD post-CART. For more info see abstract.



Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, et al.

The results in this analysis of patients with R/R-aggressive BCL relapse after anti-CD19-CAR T cells are poor and show the need for further innovative treatment strategies.



Jennifer L. Crombie, Robert A. Redd, Victor A. Chow, et al.

For more info see abstract.



Susan Prockop, Laurence Gamelin, Rajani Dinavahi, et al.

Patients whose EBV + PTLD did not respond to rituximab (HCT) or rituximab ± CT (SOT) and who responded to Tabelecleucel had long-term survival and an OS benefit similar to those who achieved CR. Tabelecleucel was well tolerated.



Anna Santarsieri, Andrew Butler, William Gelson, et al.

Treatment of monomorphic DLBL patients primarily with RM rather than R chemotherapy does not seem to compromise the OS. The number of patients who die of non-lymphoma causes - before and after lymphoma treatment - is high with both treatment approaches. The OS compares poorly to age-adjusted non-PTLD SOT recipients. For more info see abstract.